officialstreetpreachers Subscribe
Published: November 29, 2021

Study shows abortion pill ER visits are skyrocketing as FDA mulls relaxing regulations

By The Editor

Mon Nov 29, 2021 – 10:56 am EST

WASHINGTON (LifeSiteNews) — A new groundbreaking study found that ER visits following the use of abortion-inducing pills have increased over 500 percent since 2002. At the same time, the FDA is considering loosening restrictions on the drugs.

The study from the pro-life Charlotte Lozier Institute (CLI) published on November 9 found that emergency room visits following the ingestion of the abortion-inducing drugs mifepristone and misoprostol have skyrocketed over 500 percent between 2002 and 2015. Doctors now warn the Food and Drug Administration (FDA) of the drugs’ dangers ahead of a December 16 meeting where the agency will consider permanently loosening the safety regulations surrounding the infanticide pills.

The study, which analyzed Medicaid claims data, uncovered that chemical abortions pose a “22% greater risk of ER visit for any reason,” and a “53% greater risk of ER visit for an abortion-related reason,” when compared to the already potentially injurious surgical abortions.

More disturbing, “Over 60% of abortion-related ER visits following a chemical abortion in 2015 were miscoded as treatment for a miscarriage,” stated the study, suggesting the real damage done by the drugs is unclear, due to either intentional coverup or medical oversight.

CLI’s study found that the highly dangerous chemical abortions have massively increased in popularity, growing from 4.4% of total abortions to a whopping 34.1% during the study period. Even more recent 2020 figures show these drugs are responsible for over half the abortions in America.

According to Dr. James Studnicki, CLI vice president

The remainder of this article is available in its entirety at LifeSite News

The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors


Share this Article

Download the Mobile App.
Exit mobile version